The Prevalence and Drug Sensitivity of Tuberculosis among Patients Dying in Hospital in KwaZulu-Natal, South Africa: A Postmortem Study by Cohen, Ted et al.
The Prevalence and Drug Sensitivity of Tuberculosis
among Patients Dying in Hospital in KwaZulu-Natal,
South Africa: A Postmortem Study
Ted Cohen
1,2*, Megan Murray
1,2,3, Kristina Wallengren
2, Gonzalo G. Alvarez
4, Elizabeth Y. Samuel
5,
Douglas Wilson
6
1Division of Global Health Equity, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, 2Department of Epidemiology, Harvard School of
Public Health, Boston, Massachusetts, United States of America, 3Infectious Disease Unit, Massachusetts General Hospital, Boston, Massachusetts, United States of
America, 4Department of Medicine, University of Ottawa at The Ottawa Hospital, Ottawa, Ontario, Canada, 5National Health Laboratory Service, Inkosi Albert Luthuli
Central Hospital, Mayville, South Africa, 6Department of Medicine, Edendale Hospital, Pietermaritzburg, University of KwaZulu-Natal, South Africa
Abstract
Background: Tuberculosis is the leading cause of death in South Africa by death notification, but accurate diagnosis of
tuberculosis is challenging in this setting of high HIV prevalence. We conducted limited autopsies on young adults dying in
a single public hospital in the province of KwaZulu-Natal between October 2008 and August 2009 in order to estimate the
magnitude of deaths attributable to tuberculosis.
Methods and Findings: We studied a representative sample of 240 adult inpatients (aged 20–45 years) dying after
admission to Edendale Hospital. Limited autopsies included collection of respiratory tract secretions and tissue by needle
core biopsies of lung, liver, and spleen. Specimens were examined by fluorescent microscopy for acid-fast bacilli and
cultured in liquid media; cultures positive for M. tuberculosis were tested for drug susceptibility to first- and second-line
antibiotics. Ninety-four percent of our study cohort was HIV seropositive and 50% of decedents had culture-positive
tuberculosis at the time of death. Fifty percent of the participants were on treatment for tuberculosis at the time of death
and 58% of these treated individuals remained culture positive at the time of death. Of the 50% not receiving tuberculosis
treatment, 42% were culture positive. Seventeen percent of all positive cultures were resistant to both isoniazid and
rifampin (i.e., multidrug resistant); 16% of patients dying during the initiation phase of their first ever course of tuberculosis
treatment were infected with multidrug-resistant bacilli.
Conclusions: Our findings reveal the immense toll of tuberculosis among HIV-positive individuals in KwaZulu-Natal. The
majority of decedents who remained culture positive despite receiving tuberculosis treatment were infected with pan-
susceptible M. tuberculosis, suggesting that the diagnosis of tuberculosis was made too late to alter the fatal course of the
infection. There is also a significant burden of undetected multidrug-resistant tuberculosis among HIV-coinfected
individuals dying in this setting. New public health approaches that improve early diagnosis of tuberculosis and accelerate
the initiation of treatment are urgently needed in this setting.
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The emergence of HIV in South Africa has resulted in a
dramatic rise in the incidence of tuberculosis (TB). Between 1990
and 2007, as the adult HIV prevalence rose to 18.1% [1] the
incidence of tuberculosis increased more than 3-fold from 301 to
948 cases/100,000 persons/year [2]. Approximately 80% of
incident TB cases in South Africa are HIV-seropositive [2]. These
coinfected individuals are more likely to have sputum smear–
negative pulmonary or extrapulmonary TB [3,4], which can be
difficult to diagnose clinically. The World Health Organization
recommends mycobacterial culture for patients diagnosed with
sputum smear–negative tuberculosis. However, the utility of this
investigation is limited by cost and long laboratory turn-around
times.
The HIV epidemic has undermined TB control in South Africa,
and the appearance of multidrug-resistant tuberculosis (MDRTB:
resistant to the two most effective first-line drugs, isoniazid and
rifampin) and extensively drug resistant tuberculosis (XDRTB:
MDRTB with additional resistance to at least one fluoroquinolone
and one injectable drug) has further compromised the effectiveness
of standard interventions [5]. The interaction between drug-
resistant TB and HIV was highlighted by an outbreak of
nosocomial XDRTB among HIV-positive adults in Tugela Ferry,
KwaZulu-Natal (KZN), South Africa; the outbreak was associated
with a mortality rate of 98% and a median time of death at 16
days after diagnosis [6]. The diagnosis of MDRTB is laboratory-
dependent and additional costs and time are both required for a
definitive result.
TB has become the leading cause of death in South Africa by
clinically determined death notification [7]; however, the precise
role of TB in adult mortality is difficult to determine from death
notifications due to the inherent clinical difficulties in securing an
accurate diagnosis. In our study area, HIV seroprevalence is
highest among adults in the 20- to 40-y age range, and the average
life expectancy is 43 y [8]. In order to assess the magnitude of
deaths associated with TB in young adults in KZN, we conducted
a limited autopsy study of patients dying in a single public hospital
between October 2008 and August 2009.
Methods
Ethics Statement
The biomedical research ethics committee at the University of
KwaZulu-Natal and the KwaZulu-Natal Department of Health
approved the protocol for this study.
Study Setting
Edendale Hospital is an 860-inpatient-bed district and regional
facility located near the city of Pietermaritzburg in the province of
KwaZulu-Natal, South Africa. A previous study in this hospital
found that 28% of admitted patients were diagnosed with active
TB [9]. In 2006, the local incidence of TB was estimated at 1,094
cases/100,000 persons/year and the HIV prevalence among
women in antenatal clinics was more than 39% [10,11]. The total
estimated number of prevalent MDRTB cases was 2,390 in 2006
and 2,799 in 2007 (unpublished data).
Study Population
We recruited eligible decedents from a cohort of adult inpatients
at Edendale until we reached our target sample size of 240.
Eligibility criteria included age between 20 and 45 y at time of
death, death occurring after admission to either the medical or
surgical ward for inpatient treatment at Edendale Hospital, and
the consent of a family member for inclusion in the study.
Inpatients dying from trauma or obstetric complications were
excluded.
A trained research nurse approached family members of
recently deceased patients and, after informing them of the aims
and protocol of the study, invited these families to participate. For
logistical reasons, family members were approached between
08:00 and 14:00 three days a week. A detailed informed consent
document was provided in both isiZulu and English. Family
members were counseled on TB symptoms and how to access TB
testing, and were encouraged to test for HIV infection in
accordance with South African government guidelines. Close
family contacts of decedents diagnosed with MDRTB were
referred for specialist examination. HIV status of the decedent
was not routinely reported to the family. Any close contact who
signed a confidential form reporting a sexual relationship with the
deceased was informed of the HIV status of the decedent. Family
members were provided with compensation to defray the costs of
travel to and from the hospital.
Data Collection and Diagnostic Procedures
We collected demographic and medical history data from each
participant’s medical record. Information collected included age at
time of death, date of hospital admission, inpatient wards
occupied, inpatient medical diagnoses at time of death, current
TB treatment status, history of TB antibiotic exposure (‘‘new TB
cases’’ are those with less than one month of previous exposure to
TB drugs and ‘‘retreatment cases’’ are those with at least one
month of previous TB treatment before the initiation of current
TB therapy), other antibiotics received (including antiretroviral
therapy), and known MDRTB exposure prior to admission or
contact with a TB patient who had died within the previous 5 y.
The HIV status of decedents was collected from the medical
record. For individuals without a documented HIV test result, a
postmortem HIV test was done on blood or serum aspirated from
the heart or great vessels, using a dried blood spot methodology
[12–14]; accordingly, we were able to definitively classify the HIV
status of every decedent included in the study.
A limited autopsy was performed to obtain specimens for
microscopic examination for acid-fast bacilli and for M. tuberculosis
culture. Respiratory tract secretions were obtained by saline lavage
through a cricothyroid membrane puncture, and tissue was
obtained by needle core biopsies of the lung, liver, and spleen.
The liver and spleen were located using percussion and standard
anatomical surface markings [15]. Lung biopsies were obtained
through both second intercostal spaces, in the mid-clavicular line,
with the needle directed posteriorly and inferiorly, and from areas
that were dull to percussion. As greater amounts of tissue have
been demonstrated to improve yield, we obtained multiple cores
from each organ sampled [16–19]. If full-length core samples were
successfully retrieved (at least 3 cm), then only three samples were
taken, but if smaller samples were retrieved, up to five specimens
were collected from each organ. Biopsy specimens were combined
into a single pooled specimen. Samples were transported to the
NHLS referral mycobacteriology laboratory at Inkosi Albert
Luthuli Central Hospital. Standard decontamination procedures
(using N-acetyl-L-cysteine and 4% sodium hydroxide with a final
concentration of 1% for decontamination and exposure for 15–
20 min) were used for mucolysis and to minimize contamination
rates. Specimens were examined by fluorescent microscopy for
acid-fast bacilli and cultured in liquid culture media (BACTEC
MGIT 960 Becton Dickinson). Positive cultures were identified as
TB at Time of Death in KZN, South Africa
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for first- and second-line agents (isoniazid, rifampin, ethambutol,
and streptomycin, kanamycin, ofloxacin) were performed on
Middlebrook 7H10 solid media using standardized protocols
[20,21].
In order to evaluate the generalizability of our findings we
reviewed medical records to assess the HIV seropositivity rate, the
antiretroviral usage, and TB treatment status of a randomly
sampled group of decedents who were eligible but not included in
the study.
Statistical Analysis
We used bivariate and multivariate logistic regression to identify
independent associations between measured covariates and (1) the
probability of TB and (2) the probability of MDRTB among those
with TB at the time of death. We included all variables examined
in the bivariate analysis in our multivariate models and also
assessed whether or not antiretroviral therapy modified the
association between HIV and each dependent variable. Associa-
tions with p-values ,0.05 were considered statistically significant.
Data were recorded on standard paper forms and entered into a
Microsoft Access database and checked against original paper
records by two different individuals. Analysis was done using Stata
version 9.2 (College Station, TX, USA).
Results
Two hundred and forty decedents were recruited into the study
with dates of death beginning on 28 October 28 2008 and ending
on 12 August 12 2009. Over this entire time period, a total of 997
deaths occurred among inpatients who were eligible for inclusion
in the study. Table 1 displays selected characteristics of individuals
included in this sample. We found no significant difference in the
age and sex distribution of those included in the sample and those
eligible to be in the sample. The median age was 33 y with an
interquartile range (IQR) of 28–38 y for those actually included in
the study and also 33 y (IQR 28–38 y) for those eligible to be in
the study, p=0.31; the sex distribution was 44% male in the study
compared with 46% male among those eligible to be in the study)
(p=0.60). Two hundred and twenty six (94%) of the decedents in
the study were HIV-positive; 200 of the seropositive individuals
had been diagnosed with HIV before death. As such, the apparent
HIV prevalence (not including those whose HIV infections were
diagnosed after death) among those included in the study (200/
240=83%) was not statistically significantly different than the
observed HIV prevalence among a random selection of eligible
decedents who were not included in the study (126/164=77%;
p=0.13). In total, 17% of HIV-positive decedents included in the
study were receiving antiretroviral therapy at the time of death; of
the subset of participants known to be HIV positive before
autopsy, 20% were receiving antiretroviral drugs. Antiretroviral
usage was lower among participants than among the random
selection of known HIV positive decedents that were not included
in the study (38/126=30%; p-value=0.03). 15% of decedents
had at least one previous hospitalization within the past 6 mo.
Decedents died a median of 4 d (IQR 1–7 d) after admission to
the hospital.
One hundred and nineteen decedents (50%) were being treated
for TB in accordance with national guidelines at the time of death;
this was not statistically significantly different than the proportion
receiving tuberculosis treatment among the random selection of
eligible decedents that were not included in the study (77/
164=47%; p=0.55). Sixty-one percent of patients on TB
treatment were diagnosed during their final hospital admission.
The median length of hospitalization before death did not differ
significantly (p=0.85) between those diagnosed with TB and
started on anti-TB drugs during this final admission (a median of
5 d between hospitalization and death, IQR 1–9 d) and those
suspected of having TB but were not started on anti-TB regimens
and were found to be culture positive only after death (a median of
4 d between hospitalization and death, IQR 3–6 d). Fewer than
10% of decedents had either known exposures to MDRTB, recent
unexplained deaths among household contacts, or a history of
previous failed TB treatment.
Culture-Positive Tuberculosis Disease
A total of 236 specimens were examined in the laboratory; of
these, 11 (4.7%) were contaminated; this is consistent with
expected laboratory performance [19]. Smear examination of
autopsy specimens was positive in 79 (34%) of those tested,
and 110 (50%) were culture-positive for M. tuberculosis (Table 2).
Three specimens (,3%) were shown to be non-tuberculous
mycobacteria.
Among decedents receiving or not receiving antitubercular
therapy, 64 (58%) and 46 (45%) were culture positive, respectively.
Six (43%) TB suspects who were not yet on treatment had a
positive culture. Among those participants in whom TB was not
suspected at the time of death, 40 (42%) were culture positive; 39
of these patients (98%) were HIV seropositive. The top three
leading inpatient diagnoses for these unsuspected M. tuberculosis
culture-positive individuals were: pneumonia/lower respiratory
infection (25%), meningitis (18%), and gastroenteritis (15%).
In bivariate analysis, individuals receiving TB treatment and
males were significantly over-represented among those with
positive cultures at time of death (Table 3). No other measured
factors were associated with culture positivity. Among the
decedents who were positive for HIV, antiretroviral use did not
modify the probability of TB. Adjusting for each of the other
factors, males had nearly twice the odds of having a positive
culture for M. tuberculosis than females (odds ratio [OR] 1.98; 95%
confidence interval [CI] 1.12–3.52) and individuals on TB
treatment at the time of death had over 80% increased odds of
culture positivity (OR 1.82; 95% CI 1.05–3.18).
Drug Resistance
Seventeen (17%) of the M. tuberculosis isolates were MDR. Only
one XDR isolate was identified; it was found in an HIV-positive
patient with no recent history of hospitalization who was in the
initiation phase of his first course of TB chemotherapy. Only one
specimen was monoresistant to isoniazid and one monoresistant to
rifampin; all other samples that were resistant to one of these drugs
were resistant to both drugs. Table 4 displays resistance profiles
categorized by TB treatment status.
Bivariate analyses revealed that a recent previous hospitalization
and current tuberculosis therapy were each associated with an
increased probability of detecting MDR among those with
disseminated M. tuberculosis (Table 5). Multivariate analyses
revealed that among those who were culture positive, being on
current TB treatment was associated with a greater than 6-fold
increase in the odds of MDR (OR 6.56; 95% CI 1.31–32.75).
Adjusting for other factors, recent hospitalization did not remain
statistically significantly associated with MDR (OR 1.16; 95%
confidence interval 0.99–1.36).
Discussion
While TB is recognized as a major cause of early death in
KwaZulu-Natal, South Africa, our findings reveal that the toll of
TB at Time of Death in KZN, South Africa
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to prioritize diagnosis and treatment of TB, especially among those
coinfected with HIV, we found that half of the inpatients who died
at a single hospital had evidence of TB at the time of death.
Although almost half of those who died were on TB treatment at
the time of death, more than half of those on treatment still had
evidence of viable M. tuberculosis in their postmortem specimens.
Nearly half of the decedents who were not on TB treatment at the
time of death also had evidence of TB. Since needle core biopsies
of organs and respiratory specimens are unlikely to detect all cases
of disease, the proportion of decedents from which we could grow
M. tuberculosis should be considered a minimum estimate of the
actual fraction with TB at the time of death.
Our data are consistent with a growing body of literature that
shows extraordinarily high rates of TB in young HIV-positive
adults dying in African hospitals [22–24]. Although we did not
preferentially target HIV-positive individuals for inclusion, nearly
all (94%) of the decedents who were eligible and entered our study
were HIV seropositive. By the time this study had begun, more
than 7,000 adults had initiated antiretroviral therapy at Edendale
Hospital. Antiretroviral use was not associated with the probability
of culture-positive TB in our study population; however, we were
not able to determine the duration of antiretroviral therapy prior
to death.
Since we cultured all samples collected, we were able to perform
speciation and assess the drug sensitivity of the M. tuberculosis
isolates that we detected. Forty-three (70%) culture positive
patients who died while receiving TB treatment had pan-sensitive
M. tuberculosis isolated. This suggests either that the diagnosis of TB
was made too late to alter the fatal course of the infection, that
adherence was not adequate, or that drug malabsorption [25]
played some role in these poor outcomes among patients who
would otherwise be expected to respond well to standard TB
treatment [26,27].
Although previous hospitalization was not found to be
independently associated with an increased risk of MDR, the
association almost reached the level of statistical significance
(p=0.06). If there is a relationship between previous hospitaliza-
Table 1. Study population characteristics.
Category Number
Total number of participants 240
Number of females (%) [n=240] 134 (55.8%)
Median age in years (25%ile, 75%ile) [n=240] 33 (28, 38)
Number HIV seropositive (% )[n=240] 226 (94%)
Number of HIV-positive individuals receiving antiretrovirals (% among those seropositive) 39 (17%)
Number with a prior hospitalization within the last 6 months (%) [n=204] 31 (15%)
TB treatment status [n=237]
Number currently on TB treatment, new case, initiation phase (%) 83 (35%)
Number currently on TB treatment, new case, continuation phase 20 (8%)
Number currently on TB treatment, retreatment case, initiation phase 13 (5%)
Number currently on TB treatment, retreatment case, continuation phase 2 (,1%)
Number currently on TB treatment, MDRTB treatment regimen 1 (,1%)
Number with previous TB diagnosis, not on TB therapy at time of death 16 (7%)
Number with suspected TB, not on TB therapy at time of death 16 (7%)
No previous diagnosis of TB 85 (36%)
Number with known exposure to MDR [n=70] 3 (4%)
Number with a recent death within the home [n=221] 15 (7%)
Number with history of failed TB treatment [n=199] 8 (4%)
doi:10.1371/journal.pmed.1000296.t001
Table 2. Postmortem smear and culture status among participants, categorized by TB treatment status.
Smear/Culture Status On TB Treatment at Time of Death [n=117] (50%)
Not on TB Treatment at
Time of Death [n=119] (50%)
Overall smear positive 39% [46/117] 29% [33/115]
Overall culture positive 58% [64/111] 42% [46/110]
New,
Initiation
[n=81]
New,
Continuation
[n=20]
Retreatment,
Initiation
[n=13]
Retreatment,
Continuation
[n=2]
MDR
Regimen
[n=1]
Suspect TB,
not on
treatment
[n=15]
Tuberculosis
not suspected
[n=100]
Smear positive 44% [36/81] 15% [3/20] 38% [5/13] 50% [1/2] 100% [1/1] 53% [8/15] 25% [25/100]
Culture positive 65% [51/78] 26% [5/19] 55% [6/11] 50% [1/2] 100% [1/1] 43% [6/14] 42% [40/96]
doi:10.1371/journal.pmed.1000296.t002
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either a longer course of TB (either causing resistance or as a result
of resistance) or nosocomial transmission of resistant disease. An
increased risk of MDR among those on first-line TB treatment
may indicate either an increased risk of acquired resistance or that
individuals with MDR are more likely to remain culture positive
despite this treatment. That nearly one in six TB patients dying
during the initiation phase of a first TB treatment regimen were
MDR provides support for the latter hypothesis.
It is startling that 17% of the M. tuberculosis isolates we detected
were MDR and that more than 16% of patients dying during the
initiation phase of their first ever course of TB therapy have
MDRTB. These patients are quite likely to have been primarily
infected with drug-resistant M. tuberculosis and, since many had no
recent history of hospitalization, they provide additional evidence
of community transmission of drug-resistant TB [6]. The scarcity
of XDRTB in our data confirms that the Tugela Ferry outbreak
has not extended to the Edendale Hospital catchment area.
Nevertheless, these findings point to a hidden burden of MDR
disease among HIV-coinfected individuals in KZN, and the
contribution of MDRTB to early mortality in this highly
vulnerable population must be further investigated.
This study has several limitations. We obtained the clinical data
and epidemiological data on decedents from two sources: (1) their
medical charts and (2) interviews with family members. While the
medical charts were the most comprehensive clinical record
available, these data were not collected prospectively for the
purpose of the study. The accuracy of information obtained from
family members about potential TB exposures within the home
may not be reliable. Because of cost and human resource
concerns, we pooled all specimens collected from each participant
for culture; this limits our ability to identify the site of disease
involvement among those with culture-positive TB. We also did
not have resources to carry out additional histological examination
of tissues gathered at autopsy; previous studies [22–25] have
shown that additional diagnoses would likely have been made in
this population that is highly exposed to and possibly infected with
multiple opportunistic pathogens.
The prevalence of TB detected in our study should serve as an
alarm call in this setting of high HIV prevalence, antiretroviral
scale-up, and the emergence of MDR and XDRTB. The fact that
nearly half of all cases included in our survey had culture-positive
TB at the time of death, and that this proportion was essentially
the same regardless of TB treatment status or antiretroviral use
among those with HIV infection, mandates the implementation of
early, more efficacious interventions against TB and HIV.
Decreasing patient and provider delays in the diagnosis of TB in
this high HIV burden setting is essential to avert unnecessary early
Table 3. Bivariate and multivariate association with culture positive TB at time of death.
Category Unadjusted OR (95% CI) p-Value Adjusted OR (95% CI) p-Value
Male 2.07 (1.21–3.54) ,0.01 1.98 (1.12–3.52) 0.02
Age (for each additional year of age) 1.00 (0.96–1.03) 0.84 0.99 (0.95–1.03) 0.69
HIV positive 2.27 (0.68–7.60) 0.18 3.03 (0.85–10.74) 0.09
Antiretroviral use (among those with HIV) 0.66 (0.32–1.35) 0.26 0.63 (0.30–1.33) 0.22
Recent hospitalization (within previous 6 months) 1.04 ( 0.96–1.13) 0.34 1.06 (0.97–1.17) 0.18
On TB treatment at the time of death 1.84 (1.11–3.23) 0.02 1.82 (1.05–3.18) 0.03
doi:10.1371/journal.pmed.1000296.t003
Table 4. Resistance profiles for those with positive cultures, categorized by TB treatment status.
Resistance
Profile On TB Treatment at Time of Death and Culture Positive
Not on TB Treatment at
Time of Death and Culture Positive
New,
Initiation
[n=50]
New,
Continuation
[n=5]
Retreatment,
Initiation
[n=5]
Retreatment,
Continuation
[n=1]
MDR
Regimen
[n=1]
Previous TB,
not on
treatment [n=4]
Suspect TB,
not on
treatment [n=6]
No previous
TB diagnosis
[n=32]
Pan-sensitive 78% [38/49] 20% [1/5] 80% [4/5] 0% [0/1] 0% [0/1] 75% [3/4] 83% [5/6] 91% [29/32]
INH-R
a 18% [9/49] 80% [4/5] 20% [1/5] 100% [1/1] 100% [1/1] 25% [1/4] 17% [1/6] 3% [1/32]
RIF-R
a 23% [10/49] 80% [4/5] 0% [1/5] 100% [1/1] 100% [1/1] 25% [1/4] 0% [0/6] 3% [1/32]
STR-R
a 10% [5/49] 60% [3/5] 0% [1/5] 100% [1/1] 100% [1/1] 0% [0/4] 0% [0/6] 9% [3/32]
ETH-R
a 2% [1/50] 0% [0/5] 20% [1/5] 0% [0/1] 0% [0/1] 0% [0/4] 0% [0/6] 0% [0/32]
KAN-R
a 2% [1/50] 0% [0/5] 0% [0/5] 0% [0/1] 0% [0/1] 0% [0/4] 0% [0/6] 0% [0/32]
OFX-R
a 2% [1/50] 0% [0/5] 20% [1/5] 0% [0/1] 0% [0/1] 0% [0/4] 0% [0/6] 0% [0/32]
MDR
b 16% [8/49] 80% [4/5] 20% [1/5] 100% [1/1] 100% [1/1] 25% [1/4] 0% [0/6] 3% [1/32]
XDR 1 0 0 0 0 0 0 0
MOTT 1 0 1 0 0 0 0 1
aAlone or in combination with any other resistance.
bAmong those with sufficient DST results to classify MDR – does not include XDR.
doi:10.1371/journal.pmed.1000296.t004
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unknown patients should be aware that TB may occur together
with other, more acute conditions. Symptom screening, physical
examination, and evaluation of the chest radiograph for active TB
is essential [30]. Acutely ill hospitalized patients should routinely
submit sputum for TB screening with laboratory-based approaches
that increase the rapidity and/or sensitivity of diagnosis of TB such
as front-loaded (same day) smear microscopy [31], sputum
concentration methods [32], and LED fluorescence microscopy
[33]. Antiretroviral therapy prevents TB ; however, less than a
fifth of the HIV-positive decedents in this study had started
treatment. Expanded access to, and timely initiation of, antiret-
roviral therapy is essential in order to reduce TB mortality [5,34].
The substantial proportion of patients dying with MDRTB
during the initiation phase of their first course of TB therapy
highlights the difficulty of selecting appropriate treatment in
locations where drug resistance is emerging, even among those
patients for whom a diagnosis of TB is actually made. Promising
molecular tools for the rapid diagnosis of drug-resistant TB have
been developed [35,36], and their adoption in these settings has
already begun [37]. The support of the Stop TB Partnership for
field evaluation of a line probe assay for MDRTB is a significant
advance. However, the assay is recommended only for sputum
smear-positive or culture-positive specimens, which limits usage in
resource-limited high-HIV prevalent settings such as KZN. The
availability of rapid and accurate drug resistance testing must also
be accompanied by expansion of access to second-line drugs and
support to enable these patients to adhere to the lengthy treatment
regimens that are required to treat highly drug resistant TB.
The large burden of unrecognized disease among hospitalized
patients also emphasizes the need to improve infection control
both within nosocomial settings and within the community in
locations where transmission is likely to occur. Efforts to increase
the availability of TB screening for those with HIV and to conduct
intensified case finding will have the dual benefit of getting
individuals more quickly onto appropriate therapy and reducing
the opportunity for onward transmission of TB.
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Background. Every year, nearly 10 million people develop
tuberculosis—a contagious bacterial infection that affects
the lungs and other parts of the body—and nearly two
million people die from the disease. Tuberculosis is caused
by Mycobacterium tuberculosis, which spreads in airborne
droplets when people with the disease cough or sneeze. Its
characteristic symptoms are a persistent cough, weight loss,
and night sweats. Diagnostic tests for tuberculosis include
the microscopic examination of sputum samples (mucus
brought up from the lungs by coughing) for M. tuberculosis
bacilli, and mycobacterial culture (in which bacteriologists try
to grow M. tuberculosis from sputum or tissue samples).
Although tuberculosis can be cured by taking several
powerful antibiotics regularly for at least 6 months, global
efforts to control tuberculosis are being thwarted by the
emergence of strains of M. tuberculosis that are resistant to
several antibiotics (multidrug and extensively drug-resistant
tuberculosis) and by the HIV epidemic; people who are
infected with HIV, the virus that causes AIDS, are particularly
susceptible to tuberculosis because of their weakened
immune system.
Why Was This Study Done? In the past few years,
tuberculosis has become the leading recorded cause of
death in South Africa, a country where nearly a fifth of adults
are infected with HIV. There are 122,000 recorded deaths
from tuberculosis (including 94,000 deaths in HIV-positive
people) in South Africa every year. However, because the
accurate diagnosis of tuberculosis in HIV-positive people can
be difficult—they are more likely to have sputum-negative
tuberculosis than HIV-negative individuals—the true number
of people dying because of tuberculosis is likely to be higher
than the recorded number. Public-health experts in South
Africa need an accurate picture of the tuberculosis deaths to
help them improve tuberculosis control. In this postmortem
study, the researchers determine the prevalence (the
proportion of a population that has a disease) and drug
sensitivity of tuberculosis among patients dying in a public
hospital in KwaZulu-Natal, South Africa, to get a better
estimate of how many people die because of tuberculosis in
this setting.
What Did the Researchers Do and Find? The researchers
collected respiratory tract secretions and lung, liver, and
spleen samples from 240 adults who died in the Edendale
public hospital in KwaZulu-Natal over a 10-month period in
2008/9. They looked for M. tuberculosis bacilli in the samples,
tried to culture M. tuberculosis from them, and tested any
bacteria that grew for antibiotic sensitivity. They also
collected information on current tuberculosis treatment
status, previous tuberculosis treatment, and HIV status for
each deceased patient (decedent) from medical records and
from relatives. Ninety-four percent of the decedents were
HIV positive and 50% had culture-positive tuberculosis at the
time of death. Of the 50% of the decedents who were being
treated for tuberculosis, 58% were culture positive at the
time of death. A similar percentage (42%) of the decedents
who were not being treated for tuberculosis were culture
positive at the time of death. Seventeen percent of all the
positive cultures were multidrug resistant and 16% of
patients dying during their first course of tuberculosis
treatment were infected with multidrug-resistant bacteria.
Seventy percent of decedents who remained culture positive
despite receiving tuberculosis treatment were infected with
M. tuberculosis strains that were susceptible to all antibiotics.
What Do These Findings Mean? These findings reveal
the immense toll of tuberculosis among HIV-infected
individuals in this hospital in KwaZulu-Natal. They show
that many patients being treated for tuberculosis were
culture positive at death despite being infected with
antibiotic-sensitive M. tuberculosis, which suggests that
diagnoses of tuberculosis are often made too late to alter
the fatal course of infection. These findings also suggest that
multidrug-resistant tuberculosis often goes undetected
among HIV-infected individuals. Further studies are needed
to confirm these findings elsewhere in South Africa and in
other countries with a high HIV prevalence. Nevertheless,
they suggest that public-health initiatives that improve the
early diagnosis of tuberculosis, that introduce routine
screening for tuberculosis among HIV-positive patients, and
that accelerate the initiation of treatment for both
tuberculosis and HIV might reduce the global death toll
from tuberculosis.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000296.
N The World Health Organization provides information on
all aspects of tuberculosis, including information on
tuberculosis and HIV, on tuberculosis in South Africa, and
on the Stop TB Partnership (some information is in several
languages)
N The US Centers for Disease Control and Prevention has
information about tuberculosis and on tuberculosis and
HIV coinfection
N The US National Institute of Allergy and Infectious Diseases
also has detailed information on all aspects of tuberculosis
N Information is available from Avert, an international AIDS
charity, on tuberculosis and HIV
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